Ovid Therapeutics Inc. - Common Stock — Cash Flow (NASDAQ:OVID) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -51.58 M118.61 M-55.23 M-45.78 M-55.96 M-38.33 M -41.95 M Cash from investing activities 34.65 M-1.82 M-87.88 M-2.58 M54.59 M-49.85 M -49.01 M Cash from financing activities 47.07 M904.08 K180.66 K30.54 M622 K75.21 M 164.18 M Free cash flow -51.58 M118.61 M-55.23 M-45.78 M-55.96 M-38.33 M -41.95 M

News

Ovid Therapeutics Stock: Risk-Adjusted Valuation Shows Deep Discount Despite 700% Rally

Ovid Therapeutics: Buy Next-Gen GABA-Aminotransferase Inhibitor OV329, TSC/IS Expansions

Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript

3 Best Stocks to Buy Today, 4/7/2026, According to Top Analysts - TipRanks.com

Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding

Ovid Therapeutics Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:OVID) 2026-03-19

Ovid Therapeutics (OVID) Q4 Earnings and Revenues Surpass Estimates

Niagen Bioscience (NAGE) Tops Q4 Earnings and Revenue Estimates

PTC Therapeutics (PTCT) Reports Q4 Loss, Misses Revenue Estimates

Ovid Therapeutics: Bullish Post-PIPE With Two Differentiated CNS Moonshots

Ovid’s KCC2 activator shows promising safety in early trial

Ovid Therapeutics shareholders approve increase in authorized shares and related proposals